As research continues to elucidate the intricate mechanisms of SHP2’s involvement in the PD-1 pathway, novel therapeutic strategies that harness its potential could pave the way for more effective ICI resistance therapies, offering renewed hope for cancer patients facing limited treatment options. The gene discussed is PDCD1; the disease is cancer.